CYP1A2: how smoking, caffeine and stopping smoking change medicine levels

Most gene-and-medicine stories are about inherited differences. CYP1A2 shows how lifestyle changes the same enzymes. The MHRA describes tobacco smoke as containing polycyclic aromatic hydrocarbons that switch on production of several liver enzymes, with CYP1A2 the most clinically important. A smoker therefore clears certain medicines faster than a non-smoker does, so the usual dose may be too low.

Inherited variants of CYP1A2 also exist, and they interact with smoking, but the smoking effect is the part with established UK regulatory advice, so it is the focus of this guide.

The MHRA's drug safety update on smoking singles out theophylline, which has a narrow margin between a helpful and a toxic level, fluvoxamine, caffeine, warfarin and other coumarins, and the antipsychotics clozapine and olanzapine. In smokers higher doses may be needed to reach the same blood level.

These are medicines where a change in clearance matters clinically, which is why prescribers record smoking status. For many other medicines the difference is too small to change practice.

• Theophylline, used in some airway disease: levels can fall in smokers.

• Clozapine and olanzapine, used in schizophrenia and related conditions: levels can fall in smokers and rise after quitting.

• Warfarin and other coumarins: the INR may shift when smoking status changes.

• Fluvoxamine and caffeine: also cleared more quickly in smokers.

The reversal is the part patients rarely hear about. The MHRA says enzyme activity takes roughly a week to settle after stopping, and that doses of affected medicines may need to be lowered during cessation to avoid side effects. A person on clozapine who quits without the team knowing can experience drowsiness, or other signs of a rising level.

The update recommends checking smoking status when a medicine is started and again when smoking changes, then assessing whether the change is clinically significant and adjusting the dose. It adds that a temporary smoke-free period in hospital does not normally call for adjustment. The page retrieved did not discuss e-cigarettes or nicotine replacement, so this guide makes no claims about them.

Caffeine is processed by CYP1A2, and the MHRA lists it among substances cleared faster by smokers. In practice this means that someone who stops smoking may notice coffee feels stronger, with more jitteriness or poorer sleep, as the enzyme settles to its non-smoker level. That is a harmless illustration of what is happening with the prescribed medicines.

If you are cutting down caffeine for sleep or anxiety, bear in mind that the effect can shift after a change in smoking.

The MHRA also describes effects that do not depend on CYP1A2. Smoking combined with hormonal contraception raises cardiovascular risk, smoking reduces the benefit of inhaled corticosteroids in asthma, and nicotine can counteract the effect of beta-blockers. These are reasons to mention smoking at medication reviews even when no enzyme is involved.

None of this is a reason to delay quitting. It is a reason to tell the prescriber, so doses can be reviewed alongside the support offered for stopping.

If you take one of the medicines above and plan to stop smoking, tell the prescriber before your quit date. Ask whether extra blood tests, such as a level check or INR, are sensible in the first weeks.

Seek urgent help (999) for collapse, seizure, severe confusion or very slow breathing. For new drowsiness, dizziness, tremor or palpitations after a change in smoking, contact your GP, mental health team or NHS 111 the same day.